Organization | University of Rzeszow

University of Rzeszow Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Rzeszów Poland (2001)

Organization Overview

First Clinical Trial

2016

NCT03788057

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Bogumiła Pniak | Department of Anesthesiology and Intensive Care, F. Chopin Hospital in Rzeszów | Hanna Czajka | Medical Faculty, University of Rzeszów | University of Rzeszow | University of Rzeszów

Active Ingredients

Drugs in Phase 4 Trials (4)

bupivacaine (Exparel) (1 trial)

lactulose (cephulac) (1 trial)

polyethylene glycol (1 trial)

ropivacaine (naropin) (1 trial)

Drugs in Phase 3 Trials (1)

bacille calmette-guerin (1 trial)

Drugs in Other Trials (5)

budesonide (rhinocort) (1 trial)

fentanyl (Innovar) (1 trial)

oxycodone (oxycontin) (1 trial)

rocuronium (zemuron) (1 trial)

sevoflurane (ultane) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Communicable Diseases (Phase 3)

Constipation (Phase 4)

Coronavirus Infections (Phase 3)

Infections (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 10